A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour
NCT06915142 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300
Last updated 2026-01-26
Summary
This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.
Conditions
- Advanced Malignant Tumour
Interventions
- DRUG
-
HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
- DRUG
-
HRS-7058 + Cetuximab
HRS-7058 + Cetuximab
- DRUG
-
HRS-7058 + SHR-1826
HRS-7058 + SHR-1826
- DRUG
-
HRS-7058 + SHR-1826 + SHR-1316
HRS-7058 + SHR-1826 + SHR-1316
- DRUG
-
HRS-7058 + SHR-A1202
HRS-7058 + SHR-A1202
- DRUG
-
HRS-7058 + BP102
HRS-7058 + BP102
- DRUG
-
HRS-7058 + SHR-9839
HRS-7058 + SHR-9839
- DRUG
-
HRS-7058 +SHR-A2102 +SHR-1316
HRS-7058 +SHR-A2102 +SHR-1316
- DRUG
-
HRS-7058 +SHR-9839(sc)+SHR-1316
HRS-7058 +SHR-9839(sc)+SHR-1316
- DRUG
-
HRS-7058 +SHR-1316 +BP102
HRS-7058 +SHR-1316 +BP102
- DRUG
-
HRS-7058 +SHR-A2102 +BP102
HRS-7058 +SHR-A2102 +BP102
- DRUG
-
HRS-7058 +SHR-A2102 +SHR-1316 +BP102
HRS-7058 +SHR-A2102 +SHR-1316 +BP102
- DRUG
-
HRS-7058 + SHR-1316
HRS-7058 + SHR-1316
Sponsors & Collaborators
-
Shandong Suncadia Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-28
- Primary Completion
- 2026-12-31
- Completion
- 2027-10-31
Countries
- China
Study Locations
More Related Trials
-
A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults
NCT05189717 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
NCT06167694 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
NCT06470672 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
NCT06015048 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT06726148 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
NCT06970132 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
NCT03927456 ·Status: UNKNOWN ·Phase: PHASE3
-
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
NCT05656131 ·Status: SUSPENDED ·Phase: PHASE2
-
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
NCT05318339 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
NCT06788197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
NCT04247126 ·Status: COMPLETED ·Phase: PHASE1
-
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
NCT07041437 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer
NCT06819319 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
NCT07307287 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
NCT05814354 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
NCT05792410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
NCT06778031 ·Status: RECRUITING ·Phase: PHASE2
-
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
NCT06255392 ·Status: RECRUITING ·Phase: PHASE3
-
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
NCT06222879 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
NCT05349409 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT06198751 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
NCT02829372 ·Status: TERMINATED ·Phase: PHASE1